Data From Phase 2b Clinical Trial of Clazakizumab, an

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Data From Phase 2b Clinical Trial of Clazakizumab, an Anti-IL-6 Monoclonal Antibody for the Treatment of Active Psoriatic Arthritis, to be Presented at the American College of Rheumatology Annual Meeting

BOTHELL, Wash., Nov. 15, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq: ALDR ), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced Philip J. Mease, M.D. will present data from a randomized, double-blind, placebo-controlled, dose-ranging multicenter Phase 2b clinical trial evaluating the safety and efficacy of Clazakizumab in adults with active psoriatic arthritis at the American College of Rheumatology Annual Meeting at the Boston Convention and Exhibition Center in Boston, MA.

Key points:

  • The oral presentation, "A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Evaluate the Efficacy and Safety of Clazakizumab, an Anti-IL-6 Monoclonal Antibody, in Adults with Active Psoriatic Arthritis," will be presented Sunday, November 16, 2014, from 4:30 to 4:45 p.m.
  • The presentation, number 947, is part of the Spondyloarthropathies and Psoriatic Arthritis II session held in room 258 B.
  • Clazakizumab met the primary endpoint of the study, ACR20 response rate at week 16 versus placebo.
  • At week 16, ACR20 response rates were 29.3, 46.3, 52.4 and 39 percent for placebo, and 25, 100 and 200 mg Clazakizumab, respectively.
  • While there was no clear dose response, ACR 20/50/70 response rates were higher than placebo for all Clazakizumab treatment arms at week 24.
  • Clazakizumab was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data.
  • Clazakizumab is a humanized, monoclonal antibody, designed to block the pro-inflammatory molecule interleukin-6 (IL-6), which plays a key role in the inflammatory cascade leading to the inflammation, swelling, pain and destruction of large and small joints associated with arthritis.
  • Additional presentations include the posters:
    • "Validation of a Prognostic Model to Predict Structural Damage Assessed by X-ray in Patients with RA Using MRI Data from a Clinical Trial," #385, Poster Session A, Sunday, Nov. 16, 2014, from 8:30 a.m.-4:00p.m.
    • "Impact of Rapid Attainment of Target Measures in Rheumatoid Arthritis on Patient Reported Outcomes," #1362, Poster Session B, Monday, Nov. 17, 2014, from 8:30 a.m.-4:00p.m.

Quote :

Randall C. Schatzman, Ph.D., President and Chief Executive Officer, Alder BioPharmaceuticals, said, "The results of this study in psoriatic arthritis are an important milestone for the development of Clazakizumab. Having recently regained control of this novel therapy, we are excited to share this promising data and plan to announce top-line data from a follow-on Phase 2b dose-ranging trial for the treatment of rheumatoid arthritis in the first half of 2015. At this time, based on positive data for Clazakizumab reported to date, we are actively seeking a strategic partner that can further develop and commercialize this promising therapeutic in autoimmune and inflammatory diseases."

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's ALD403 inhibits a well-validated molecule shown to trigger migraine attacks, calcitonin gene-related peptide (CGRP), and is now undergoing clinical testing. Alder advanced ALD403 into a Phase 2b trial for the treatment of chronic migraines and plans to initiate a Phase 2b trial for the treatment of frequent episodic migraines in the first half of 2015. Alder's second program, Clazakizumab, previously known as ALD518, is designed to block the pro-inflammatory cytokine IL-6 and has completed a Phase 2b clinical study. For more information, please visit http://www.alderbio.com .

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding our expectations for the initiation of future clinical trials, data availability from ongoing clinical trials and the potential of ALD403 and Clazakizumab to address the unmet medical needs of patients. All forward-looking statements included in this press release are based on our management's beliefs and assumptions and on information currently available to our management, and we assume no obligation to update any such forward-looking statements. Any or all of our forward-looking statements in this press release may turn out to be wrong and actual events or results may differ materially. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and other factors. In evaluating these statements, you should specifically consider various factors, including the risks outlined under the caption "Risk Factors" set forth in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, which was filed with the Securities and Exchange Commission (the "SEC") on November 3, 2014, and is available on the SEC's website at www.sec.gov . Additional information will also be set forth in our other reports and filings we will make with the SEC from time to time. We caution investors that our business and financial performance are subject to substantial risks and uncertainties.

Media Contacts: David Schull or Andrea Flynn, Ph.D. Russo Partners (212) 845-4271 (646) 942-5631 Investor Relations Contact: Sarah McCabe Stern Investor Relations, Inc. (212) 362-1200

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rehab Equipment Growth Meets a Brutal Access Gap

Updated Category News Views 89

Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 88

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 114

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
DocLinq Takes Aim at Care Gaps Between Office Visits

Updated Category News Views 149

Healthcare's most expensive loose ends often pile up after the appointment ends. DocLinq, launched from Columbia, Maryland, is taking a run at that awkward stretch between office visits, where records sit in separate systems, chronic-care follow-up gets uneven, and patients are expected to remember far more than any human reasonably can. This is not a story about AI...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 286

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 108

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 128

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 125

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 36

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 117

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading

Top 5 Most Recently Viewed Articles

Current Trends in Short Interest Impacting PayPal Stock

Updated Category News Views 262

Understanding PayPal Holdings Inc and Its Market Position PayPal Holdings Inc (NYSE: PYPL) remains a prominent player in the digital payments space, continuing to see fluctuations in its market sentiment. Recently, the company has noted a significant increase in short interest as a percentage of float, climbing by 11.57%. This rise has brought the total number of shares...

Continue Reading
WillScot Plans Upcoming Earnings Call and Webcast for Q1

Updated Category News Views 152

WillScot Holdings Corporation to Share Q1 Results WillScot Holdings Corporation, a renowned leader in providing innovative temporary flexible space solutions, has announced its schedule for releasing the financial results for the first quarter of 2025. This eagerly anticipated announcement is set to take place on May 1, 2025, after market close, allowing investors and...

Continue Reading
Denarius' Bold Move: Debentures Target Early Exit

Updated Category News Views 53

Treading Against Debentures: Denarius' Maneuver Denarius Metals Corp. doesn't seem keen on playing it safe with convertible debentures tying up its business. Jaw-dropping numbers in news like this make you stop and wonder: Is this strategy brilliance, or just a roll of the dice? Time-Pressured Decisions Denarius Metals, trading as OTCQX: DNRSF, has kicked off a whirlwind...

Continue Reading
Katten Partners Recognized Among Top Experts in Crypto Sector

Updated Category News Views 185

Katten Partners Shine in Crypto Industry Recognition Katten, a well-respected law firm, has gained significant attention for its leadership in the evolving digital asset landscape. Three of its distinguished partners have been recognized by Citywealth, a leading publication in the private wealth sector, for their exceptional contributions to the cryptocurrency domain. The...

Continue Reading
Anticipating Logitech International's Earnings Success

Updated Category News Views 160

Anticipating Logitech International's Earnings Success Logitech International (NASDAQ: LOGI) is gearing up for its next quarterly earnings announcement, and investors are keenly observing potential developments. As the company prepares to report earnings, expectations are high for positive news regarding financial forecasts and results. Analyst Predictions for Earnings...

Continue Reading